Nitric oxide mediates the anticonvulsant effects of thalidomide on pentylenetetrazole-induced clonic seizures in mice

Epilepsy and Behavior

Volumn 34, Issue , 2014, Pages 99-104

  Payandemehr, Borna ^a,b   Rahimian, Reza ^a,c   Gooshe, Maziar ^a,b   Bahremand, Arash ^d   Gholizadeh, Ramtin ^a   Berijani, Sina ^a   Ahmadi Dastgerdi, Mohammad ^a   Aminizade, Mehdi ^a   Sarreshte Dari, Ali ^a   Dianati, Vahid ^e   Amanlou, Massoud ^e   Dehpour, Ahmad Reza ^a,f  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aminoguanidine; L Arginine nitric oxide pathway; Mice; Neuronal NOS; Seizure; Thalidomide

Indexed keywords

AMINOGUANIDINE; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PENTETRAZOLE; THALIDOMIDE; ANTICONVULSIVE AGENT; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; LOW DRUG DOSE; MALE; MEDIATOR; MODULATION; MOUSE; NMRI MOUSE; NONHUMAN; PENTYLENETETRAZOLE-INDUCED SEIZURE; POST HOC ANALYSIS; SEIZURE THRESHOLD; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; METABOLISM; SEIZURES;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTYLENETETRAZOLE; SEIZURES; THALIDOMIDE;

EID: 84898914279     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.03.020     Document Type: Article

References (41)

1. Matthews S.J., McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003, 25:342-395.
2. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
3. Prommer E.E., Twycross R., Mihalyo M., Wilcock A. Thalidomide. J Pain Symptom Manage 2011, 41:140-145.
4. Qin X.-Y., Akanuma H., Wei F., Nagano R., Zeng Q., Imanishi S., et al. Effect of low-dose thalidomide on dopaminergic neuronal differentiation of human neural progenitor cells: a combined study of metabolomics and morphological analysis. Neurotoxicology 2012, 33(5):1375-1380.
5. Palencia G., Martinez-Juarez I.E., Calderon A., Artigas C., Sotelo J. Thalidomide for treatment of refractory epilepsy. Epilepsy Res 2010, 92:253-257.
6. He P., Cheng X., Staufenbiel M., Li R., Shen Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PLoS One 2013, 8:e55091.
7. Palencia G., Rubio C., Custodio-Ramirez V., Paz C., Sotelo J. Strong anticonvulsant effect of thalidomide on amygdaloid kindling. Epilepsy Res 2011, 95:263-269.
8. Zhang L., Qu Y., Tang J., Chen D., Fu X., Mao M., et al. PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro. Brain Res 2010, 1357:157-165.
9. Majumder S., Rajaram M., Muley A., Reddy H.S., Tamilarasan K.P., Kolluru G.K., et al. Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase. Br J Pharmacol 2009, 158:1720-1734.
10. Siamwala J.H., Veeriah V., Priya M.K., Rajendran S., Saran U., Sinha S., et al. Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep 2012, 2:679.
11. Tamilarasan K.P., Kolluru G.K., Rajaram M., Indhumathy M., Saranya R., Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 2006, 7:17.
12. Shimazawa R., Sano H., Tanatani A., Miyachi H., Hashimoto Y. Thalidomide as a nitric oxide synthase inhibitor and its structural development. Chem Pharm Bull 2004, 52:498-499.
13. Taliyan R., Sharma P.L. Possible mechanism of protective effect of thalidomide in STZ-induced-neuropathic pain behavior in rats. Inflammopharmacology 2012, 20:89-97.
14. Corrêa JOdA, Aarestrup B.J.V., Aarestrup F.M. Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE). Exp Neurol 2010, 226:15-23.
15. Noguchi T., Sano H., Shimazawa R., Tanatani A., Miyachi H., Hashimoto Y. Phenylhomophthalimide-type NOS inhibitors derived from thalidomide. Bioorg Med Chem Lett 2004, 14:4141-4145.
16. Payandemehr B., Bahremand A., Rahimian R., Ziai P., Amouzegar A., Sharifzadeh M., et al. 5-HT3receptor mediates the dose-dependent effects of citalopram on pentylenetetrazole-induced clonic seizure in mice: involvement of nitric oxide. Epilepsy Res 2012, 101(3):217-227.
17. Riazi K., Roshanpour M., Rafiei-Tabatabaei N., Homayoun H., Ebrahimi F., Dehpour A.R. The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br J Pharmacol 2006, 147:935-943.
18. Najafi S., Payandemehr B., Tabrizian K., Shariatpanahi M., Nassireslami E., Azami K., et al. The role of nitric oxide in the PKA inhibitor induced spatial memory deficits in rat: involvement of choline acetyltransferase. Eur J Pharmacol 2013, 714:478-485.
19. Bahremand A., Nasrabady S.E., Ziai P., Rahimian R., Hedayat T., Payandemehr B., et al. Involvement of nitric oxide-cGMP pathway in the anticonvulsant effects of lithium chloride on PTZ-induced seizure in mice. Epilepsy Res 2010, 89:295-302.
20. Bahremand A., Ziai P., Khodadad T.K., Payandemehr B., Rahimian R., Ghasemi A., et al. Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: involvement of l-arginine/nitric oxide pathway. Epilepsy Behav 2010, 18:186-192.
21. Patent GB 768 821 (Chemie Grünenthal; 20. Februar 1957).
22. Payandemehr B., Rahimian R., Bahremand A., Ebrahimi A., Saadat S., Moghaddas P., et al. Role of nitric oxide in additive anticonvulsant effects of agmatine and morphine. Physiol Behav 2013, 118:52-57.
23. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. a comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002, 50:105-123.
24. Bahremand A., Payandemehr B., Rahimian R., Ziai P., Pourmand N., Loloee S., et al. The role of 5-HT3 receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 2011, 21(2):122-127.
25. Bahremand A., Ziai P., Payandemehr B., Rahimian R., Amouzegar A., Khezrian M., et al. Additive anticonvulsant effects of agmatine and lithium chloride on pentylenetetrazole-induced clonic seizure in mice: involvement of [alpha] 2-adrenoceptor. Eur J Pharmacol 2011, 666(1-3):93-99.
26. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
27. Palencia G., Calderon A., Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J Neurol Sci 2007, 258:128-131.
28. Kim J.H., Scialli A.R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011, 122:1-6.
29. Dimopoulos M.A., Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004, 117:508-515.
30. Hyakkoku K., Nakajima Y., Izuta H., Shimazawa M., Yamamoto T., Shibata N., et al. Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience 2009, 159:760-769.
31. Tweedie D., Frankola K.A., Luo W., Li Y., Greig N.H. Thalidomide analogues suppress lipopolysaccharide-induced synthesis of TNF-α and nitrite, an intermediate of nitric oxide, in a cellular model of inflammation. Open Biochem J 2011, 5:37.
32. Baran L., Siwanowicz J., Przegalinski E. Effect of nitric oxide synthase inhibitors and molsidomine on the anticonvulsant activity of some antiepileptic drugs. Pol J Pharmacol 1997, 49:363-368.
33. Przegalinski E., Baran L., Siwanowicz J. The role of nitric oxide in chemically- and electrically-induced seizures in mice. Neurosci Lett 1996, 217:145-148.
34. De Sarro G.B., Donato Di Paola E., De Sarro A., Vidal M.J. Role of nitric oxide in the genesis of excitatory amino acid-induced seizures from the deep prepiriform cortex. Fundam Clin Pharmacol 1991, 5:503-511.
35. Osonoe K., Mori N., Suzuki K., Osonoe M. Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazol-induced seizures in rats. Brain Res 1994, 663:338-340.
36. Nidhi G., Balakrishnan S., Pandhi P. Role of nitric oxide in electroshock and pentylenetetrazole seizure threshold in rats. Methods Find Exp Clin Pharmacol 1999, 21:609-612.
37. Sardo P., D'Agostino S., Rizzo V., Carletti F., Lonobile G., Ferraro G. In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs. J Neural Transm 2009, 116:831-839.
38. Talarek S., Fidecka S. Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice. Pol J Pharmacol 2003, 55:181-191.
39. Robello M., Amico C., Bucossi G., Cupello A., Rapallino M.V., Thellung S. Nitric oxide and GABAA receptor function in the rat cerebral cortex and cerebellar granule cells. Neuroscience 1996, 74:99-105.
40. Badamtseren B., Odkhuu E., Koide N., Haque A., Naiki Y., Hashimoto S., et al. Thalidomide inhibits interferon-γ-mediated nitric oxide production in mouse vascular endothelial cells. Cell Immunol 2011, 270:19-24.
41. Fakhfouri G., Rahimian R., Ghia J.-E., Khan W.I., Dehpour A.R. Impact of 5-HT3receptor antagonists on peripheral and central diseases. Drug Discov Today 2012, 17:741-747.